CT-Perfusion for Neurological Diagnostic Evaluation

NCT ID: NCT03098511

Last Updated: 2024-04-23

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 333 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-04-25
• Study Completion Date: 2024-08-31

Brief Summary

For the purpose of organ donation after neurological determination of death (NDD), death must be declared using a set of standardized clinical criteria. When a full clinical evaluation cannot be completed, additional neuroimaging ancillary testing is required. The ideal ancillary test for NDD would demonstrate no cerebral blood flow, be free of false-positive and false negative results, rapid, safe, readily available, non-invasive, and inexpensive. No current ancillary test for NDD meets these criteria. Computed tomography (CT) perfusion has the characteristics of an ideal test for NDD, but has not been evaluated for routine clinical use for NDD.

The overarching goal of this project is to improve the NDD process by establishing CT-perfusion as the ideal ancillary test. A large prospective Canadian multi-centre diagnostic cohort study will be conducted to validate CT-perfusion for the neurological determination of death.

Specific objectives are:

Primary objective: To determine diagnostic accuracy of CT-perfusion compared to complete clinical evaluation for NDD.

Secondary objectives: 1) To confirm the safety of performing CT-perfusion in critically ill patients suspected of being neurologically deceased; 2) To establish the CT-perfusion inter-rater reliability for NDD; 3) To evaluate the diagnostic accuracy of CT-angiography compared to complete clinical evaluation and to CT-perfusion for NDD; 4) To describe the clearance of commonly used sedatives and narcotics in the setting of NDD; and 5) to investigate biological changes (inflammatory and nanovesicles) that occur in humans during the brain dying process.

Detailed Description

The investigators will conduct a large prospective Canadian multi-centre diagnostic cohort study. The primary diagnostic test evaluated will be CT-perfusion. The reference standard will be the complete clinical evaluation of brainstem functions. Comatose patients at high risk of neurological death exempt of confounding factors (e.g. hypothermic patients, use of long-acting sedatives, etc.) will be included. All patients will undergo CT-perfusion of the head (with CT-angiography reconstructions) followed by a complete NDD assessment. Both CT-perfusion and the clinical exam will be performed by independent assessors blinded from each others' interpretation. The primary endpoints will be the sensitivity and specificity of CT-perfusion to confirm NDD. Safety endpoints will be CT-perfusion -related adverse events (i.e. contrast-induced kidney injury, new hemodynamic instability while undergoing CT-perfusion). The true negative, true positive, false negative and false positive for CT-angiography obtained from the CT-perfusion source images when compared to the reference standard as well as when compared to the CT-Perfusion will also be reported. The sensitivity and specificity of CT-angiography compared to the reference standard and to CT-perfusion along with corresponding 95% confidence intervals will be calculated. Individual patient and population pharmacokinetics of analgesics and sedatives will be determined. To better investigate the impact of residual circulating sedative or narcotic levels on the accuracy of CT-Perfusion and CT-Angiography, Receiver Operating Characteristics (ROC) curves for varying levels of narcotic or sedative thresholds and compute the ROC area under the curve for each threshold will be plotted. To assess the immune phenotype, peripheral blood mononuclear cells activation will be evaluated by flow cytometry and cytokines by multiplex analyses. Nanovesicles fraction will be isolated from the plasma by ultracentrifugation and antigenic content and enzymatic activity. The plasma will finally be analysed by ELISAs and multiplex analyses to determine the levels of pro-inflammatory cytokines.

Conditions

Neurological Determination of Death

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Neurological Diagnostic Evaluation

Exams performed according to a determined schedule following admission in the intensive care unit in order to validate CT-perfusion as an accurate ancillary test for neurological diagnostic.

Group Type: OTHER

Neurological Diagnostic Evaluation

Intervention Type: DIAGNOSTIC_TEST

Clinical Data:

• Demographic data
• Daily data (clinical exams, laboratory data)
• Drug administration
• Additional clinical or ancillary neurological determination test

Diagnostic Intervention:

• CT-Perfusion
• CT-Angiography reconstructions

Reference Standard:

• Clinical Neurological Exam

Blood Samples (Pharmacokinetics, Inflammatory & Nanovesicles Parameters):

• At the time of patient enrolment
• 6 hours after patient enrolment
• At the time of the clinical neurological exam

Secondary Outcome measures at 6 months:

• extended Glasgow Outcome Scale (GOSe)
• modified Rankin Scale (mRS)

Interventions

Neurological Diagnostic Evaluation

Clinical Data:

• Demographic data
• Daily data (clinical exams, laboratory data)
• Drug administration
• Additional clinical or ancillary neurological determination test

Diagnostic Intervention:

• CT-Perfusion
• CT-Angiography reconstructions

Reference Standard:

• Clinical Neurological Exam

Blood Samples (Pharmacokinetics, Inflammatory & Nanovesicles Parameters):

• At the time of patient enrolment
• 6 hours after patient enrolment
• At the time of the clinical neurological exam

Secondary Outcome measures at 6 months:

• extended Glasgow Outcome Scale (GOSe)
• modified Rankin Scale (mRS)

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

1. Adults 18 years and older

2. Admitted in the intensive care unit with a brain injury

3. Glasgow Coma Scale (GCS) = 3

4. Sedation stopped for at least 6 hours

Exclusion Criteria

1. Patients with the following contraindications to CT-perfusion will be excluded from the study:

• Pregnancy
• Contrast allergy
• Clinician refuses inclusion because of kidney injury.

2. Patients with any of the following confounding factors precluding complete clinical neurological evaluation will be excluded from the study:

• Cervical fracture above C6
• Significant facial trauma limiting cranial nerve examination
• Hypothermia < 34 °C
• Use of intravenous barbiturates at any time since admission
• Unresuscitated shock
• Peripheral nerve or muscle dysfunction or neuromuscular blockade potentially accounting for unresponsiveness
• Anoxic brain injury < 24h (or 72h if therapeutic hypothermia)
• Attending physician disagrees to conduct an apnea test
• Any other abnormalities deemed a confounding factor for NDD by the attending clinician

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

Sponsor Role: collaborator

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michaël Chassé, MD PhD FRCPC

Role: PRINCIPAL_INVESTIGATOR

Centre hospitalier de l'Université de Montréal (CHUM)

Jai JS Shankar, MD MSc FRCPC

Role: PRINCIPAL_INVESTIGATOR

University of Manitoba

Locations

Foothills Medical Centre

Calgary, Alberta, Canada

Winnipeg Health Sciences Centre

Winnipeg, Manitoba, Canada

Queen Elizabeth II Health Sciences Centre

Halifax, Nova Scotia, Canada

William Osler Health System

Brampton, Ontario, Canada

Hamilton Health Sciences Center

Hamilton, Ontario, Canada

Kingston General Hospital

Kingston, Ontario, Canada

London Health Sciences Centre

London, Ontario, Canada

The Ottawa Hospital

Ottawa, Ontario, Canada

St-Michael's Hospital

Toronto, Ontario, Canada

Centre Hospitalier de l'Université de Montréal (CHUM)

Montreal, Quebec, Canada

McGill University Health Centre

Montreal, Quebec, Canada

Montreal Neurological Institute and Hospital

Montreal, Quebec, Canada

CHU de Québec - Université Laval

Québec, Quebec, Canada

Centre Hospitalier Universitaire de Sherbrooke

Sherbrooke, Quebec, Canada

Countries

Canada

Other Identifiers

CE 16.379

Identifier Type: -

Identifier Source: org_study_id